Cell therapy weekly: FDA aims to advance gene therapies and T cells reprogrammed without the use of viral vectors
Cell therapy weekly: ALS stem cell therapy will not be available under ‘Right to Try’ and new collaboration advances T-cell cancer therapies
Cell therapy weekly: Positive outlook for oncology patients receiving immunotherapies
Cell therapy weekly: CCRM and GE Healthcare to assist in scale-up of degenerative disc disease therapy
Cell therapy weekly: FDA indicates more guidance is to come on cell therapy manufacture
Cell therapy weekly: Novo Nordisk continues to investigate stem cell therapies for chronic diseases and Kite expands manufacturing capability
In this interview, filmed at the World Advanced Therapies and Regenerative Medicine Congress (16–18 May, London, UK), Hatim Hemeda, CEO, PL Bioscience, discusses the importance of xeno-free cell culture media.